Bcl-xL is an oncogenic driver in colorectal cancer

[1]  Jonathan C. Fuller,et al.  The HMGB1 protein induces a metabolic type of tumour cell death by blocking aerobic respiration , 2016, Nature Communications.

[2]  F. Sinicrope,et al.  The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism* , 2015, The Journal of Biological Chemistry.

[3]  I. Marzo,et al.  Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside. , 2015, Current opinion in pharmacology.

[4]  L. Lam,et al.  Genomic analysis and selective small molecule inhibition identifies BCL-XL as a critical survival factor in a subset of colorectal cancer , 2015, Molecular Cancer.

[5]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[6]  Aziz Zaanan,et al.  Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells , 2014, Molecular Cancer Research.

[7]  D. Jäger,et al.  Targeting cell death signaling in colorectal cancer: current strategies and future perspectives. , 2014, World journal of gastroenterology.

[8]  W. Roth,et al.  The soluble Decoy Receptor 3 is regulated by a PI3K-dependent mechanism and promotes migration and invasion in renal cell carcinoma , 2013, Molecular Cancer.

[9]  D. Jäger,et al.  Beyond Cell Death – Antiapoptotic Bcl-2 Proteins Regulate Migration and Invasion of Colorectal Cancer Cells In Vitro , 2013, PloS one.

[10]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[11]  D. Jäger,et al.  Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice. , 2012, Journal of hepatology.

[12]  A. Watson,et al.  TNF‐α–induced intestinal epithelial cell shedding: implications for intestinal barrier function , 2012, Annals of the New York Academy of Sciences.

[13]  S. Ming,et al.  Prognostic significance of Bcl-xL gene expression in human colorectal cancer. , 2011, Acta histochemica.

[14]  D. Green,et al.  A unified model of mammalian BCL-2 protein family interactions at the mitochondria. , 2011, Molecular cell.

[15]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[16]  V. Duronio,et al.  MCL-1 localizes to sites of DNA damage and regulates DNA damage response , 2010, Cell cycle.

[17]  J. Habbema,et al.  Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. , 2009, Journal of the National Cancer Institute.

[18]  Yu Fan,et al.  Significance of Bcl-xL in human colon carcinoma. , 2008, World journal of gastroenterology.

[19]  Markus F Neurath,et al.  An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression , 2007, Nature Protocols.

[20]  M. Neurath,et al.  High resolution colonoscopy in live mice , 2006, Nature Protocols.

[21]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[22]  V. Duronio,et al.  A proteolytic fragment of Mcl-1 exhibits nuclear localization and regulates cell growth by interaction with Cdk1. , 2005, The Biochemical journal.

[23]  N. Agnantis,et al.  Diffuse large B-cell lymphomas with germinal center B-cell-like differentiation immunophenotypic profile are associated with high apoptotic index, high expression of the proapoptotic proteins bax, bak and bid and low expression of the antiapoptotic protein bcl-xl , 2004, Modern Pathology.

[24]  S. Cory,et al.  The Bcl2 family: regulators of the cellular life-or-death switch , 2002, Nature Reviews Cancer.

[25]  I. D'Agnano,et al.  c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. , 2001, The American journal of pathology.

[26]  E. Yeh,et al.  Regulation of Apoptosis and Cell Cycle Progression by MCL1 , 2000, The Journal of Biological Chemistry.

[27]  R. Poczatek,et al.  Prognostic significance of Bcl‐2 expression and p53 nuclear accumulation in colorectal adenocarcinoma , 1997, International journal of cancer.

[28]  John Calvin Reed,et al.  Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. , 1996, Cancer research.

[29]  John Calvin Reed,et al.  Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. , 1996, The American journal of pathology.

[30]  M. Peck-Radosavljevic,et al.  Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. , 2006, Journal of hepatology.

[31]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.